Third quarter (30-JUL-2018 – 30-SEP-2018) 

Net sales 0 (0)

Result after tax decreased to -1,013,567 (-422,162)

Result per share decreased to -0.14 (-0.06)

Equity ratio amounted to -0.84 (0.22)

Nine months (01-JAN-2018 – 30-SEP-2018)

Net sales 0 (0)

Result after tax decreased to -4,361,298 (-541,233)

Result per share decreased to -0.46 (-0.06)

Equity ratio amounted to -0.84 (0.22)

Highlights during Q3 2018

• 05JUL18: The extraordinary shareholders" meeting resolved to elect Thomas Feldthus as new ordinary board member.
• 05JUL18: The extraordinary general meeting resolved to raise up to SEK 26 million through an Initial Public Offering (“IPO”) at Spotlight Stock Market (“Spotlight”), Sweden.
• 06AUG18: Scandion Oncology signs agreement with Sedermera Fondkommission regarding an IPO at Spotlight.
• AUG18: Scandion Oncology hires Peter Michael Vestlev, MD as new Chief Medical Officer.
• 06SEPT18: Scandion Oncology files a new patent application covering a new Mechanisms of Action of SCO-101 in inhibiting anti-cancer drug resistance.

Highlights after the balance sheet date

• 01OCT18: Scandion Oncology is approved for listing at Spotlight.
• 16OCT18: Scandion Oncology files a new patent application covering a second indication for SCO-101. The second indication is a non-cancer indication where there is a significant medical need and market potential.
• 23OCT18: Through the new share issue, Scandion Oncology will receive approx. 1,500 new shareholders and SEK 26 million. Scandion Oncology’s new share issue was oversubscribed more than 4 times prior to the listing on Spotlight.
• 08NOV18: Scandion Oncology has its first day of public trading at Spotlight.
• 13NOV18: Scandion Oncology receives a small but important EU grant.
• 16NOV18: Scandion Oncology receives an EU-Upstart grant.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. It has been shown in vitro-studies that SCO-101 restores chemotherapy sensitivity in resistant cells.